Urinary excretion of liver-type fatty acid-binding protein reflects the severity of sepsis

被引:0
|
作者
Sato E. [1 ]
Kamijo-Ikemori A. [2 ,4 ]
Oikawa T. [3 ]
Okuda A. [3 ]
Sugaya T. [3 ,4 ]
Kimura K. [5 ]
Nakamura T. [1 ,4 ]
Shibagaki Y. [4 ]
机构
[1] Division of Nephrology, Department of Medicine, Shinmatsudo Central General Hospital, 1-380 Shinmatsudo, Matsudo,Chiba
[2] Department of Anatomy, St. Marianna University School of Medicine, Sugao, Miyamae-Ku, Kawasaki,Kanagawa
[3] Cmic Holdings Co. Ltd., Hamamatsucho Bldg., 1-1-1 Shibaura, Minato-ku, Tokyo
[4] Department of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Sugao, Miyamae-Ku, Kawasaki, 216-8511, Kanagawa
[5] Department of Internal Medicine, Japan Community Health Care Organization, Tokyo Takanawa Hospital, Tokyo
关键词
AKI; Biomarker; L-FABP; Oxidative stress; POC; Sepsis;
D O I
10.1186/s41100-017-0107-x
中图分类号
学科分类号
摘要
Sepsis due to microbial invasion often causes multiple organ failure (MOF), including acute kidney injury (AKI), with high mortality rates in serious cases. Hence, there is an urgent need for diagnostic biomarkers that can be used to rapidly, accurately, and easily detect sepsis to identify the condition early and guide the selection of appropriate treatment. Liver-type fatty acid-binding protein (L-FABP), which localizes in renal proximal tubules, is excreted into the urine in response to oxidative stress-induced tubular injury. Because of this mechanism, L-FABP has been reported to be a useful urinary biomarker not only for renal disease but also for the severity of sepsis. Based on this concept, we developed a new L-FABP point-of-care (POC) assay kit that can be used to rapidly measure human L-FABP in the urine to further improve the usefulness of this biomarker in clinical settings. In this review, we describe the molecular mechanisms of L-FABP, its clinical usefulness, and the performance of the POC assay kit. © 2017 The Author(s).
引用
收藏
相关论文
共 50 条
  • [31] Performance of Urinary Liver-Type Fatty Acid-Binding Protein in Acute Kidney Injury: A Meta-analysis
    Susantitaphong, Paweena
    Siribamrungwong, Monchai
    Doi, Kent
    Noiri, Eisei
    Terrin, Norma
    Jaber, Bertrand L.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2013, 61 (03) : 430 - 439
  • [32] Urinary liver-type fatty acid-binding protein in two dogs with acquired Fanconi syndrome: A case report
    Takashima, Satoshi
    Nasu, Tomomi
    Ohata, Keiichi
    Oikawa, Tsuyoshi
    Sugaya, Takeshi
    Kobatake, Yui
    Shibata, Sanae
    Nishii, Naohito
    OPEN VETERINARY JOURNAL, 2022, 12 (06) : 864 - 867
  • [33] Association of urinary liver-type fatty acid-binding protein with outcomes after adrenalectomy for unilateral primary aldosteronism
    Wu, Chun-Yi
    Wu, Ming-Ju
    Chen, Cheng-Hsu
    Yu, Tung-Min
    Chuang, Ya-Wen
    Lin, Yen-Hung
    Wu, Jui-Teng
    Shiao, Chih-Chung
    Wu, Vin-Cent
    CLINICA CHIMICA ACTA, 2023, 548
  • [34] Urinary Fatty Acids and Liver-Type Fatty Acid Binding Protein in Diabetic Nephropathy
    Sasaki, Hiroyo
    Kamijo-Ikemori, Atsuko
    Sugaya, Takeshi
    Yamashita, Kayoko
    Yokoyama, Takeshi
    Koike, Jyunki
    Sato, Takeo
    Yasuda, Takashi
    Kimura, Kenjiro
    NEPHRON CLINICAL PRACTICE, 2009, 112 (03): : C148 - C156
  • [35] Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy
    Nakamura, T
    Sugaya, T
    Kawagoe, Y
    Ueda, Y
    Osada, S
    Koide, H
    DIABETES CARE, 2005, 28 (11) : 2728 - 2732
  • [36] The Possibility of Urinary Liver-Type Fatty Acid-Binding Protein as a Biomarker of Renal Hypoxia in Spontaneously Diabetic Torii Fatty Rats
    Tanabe, Jun
    Ogura, Yuji
    Nakabayashi, Mikie
    Nagai, Yoshio
    Watanabe, Shiika
    Sugaya, Takeshi
    Ohata, Keiichi
    Ichikawa, Daisuke
    Inoue, Kazuho
    Hoshino, Seiko
    Kimura, Kenjiro
    Shibagaki, Yugo
    Ono, Yumie
    Kamijo-Ikemori, Atsuko
    KIDNEY & BLOOD PRESSURE RESEARCH, 2019, 44 (06): : 1476 - 1492
  • [37] Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease
    Nakamura, Tsukasa
    Sugaya, Takeshi
    Kawagoe, Yasuhiro
    Suzuki, Tsukasa
    Ueda, Yoshihiko
    Koide, Hikaru
    Inoue, Teruo
    Node, Koichi
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2007, 333 (06): : 321 - 326
  • [38] Urinary Level of Liver-Type Fatty Acid Binding Protein Reflects the Degree of Tubulointerstitial Damage in Polycystic Kidney Disease
    Watanabe, Shiika
    Ichikawa, Daisuke
    Sugaya, Takeshi
    Ohata, Keiichi
    Inoue, Kazuho
    Hoshino, Seiko
    Kimura, Kenjiro
    Shibagaki, Yugo
    Kamijo-Ikemori, Atsuko
    KIDNEY & BLOOD PRESSURE RESEARCH, 2018, 43 (06): : 1716 - 1729
  • [39] Urinary liver-type fatty acid-binding protein: Discrimination between IgA nephropathy and thin basement membrane nephropathy
    Nakamura, T
    Sugaya, T
    Ebihara, I
    Koide, H
    AMERICAN JOURNAL OF NEPHROLOGY, 2005, 25 (05) : 447 - 450
  • [40] Incremental short maximal exercise increases urinary liver-type fatty acid-binding protein in adults without CKD
    Kosaki, Keisei
    Kamijo-Ikemori, Atsuko
    Sugaya, Takeshi
    Kumamoto, Shota
    Tanahashi, Koichiro
    Kumagai, Hiroshi
    Kimura, Kenjiro
    Shibagaki, Yugo
    Maeda, Seiji
    SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS, 2020, 30 (04) : 709 - 715